



Potential Therapeutic Target for Atherosclerosis

Guest Editor:

Dr. Catherine Martel

1. Montreal Heart Institute,
Montréal, QC H1T1C8, Canada
2. Department of Medicine,
Faculty of Medicine, Université de
Montréal, Montréal, QC H3C 3J7,
Canada

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Dear Colleagues,

Atherosclerosis, the main underlying cause of cardiovascular disease (CVD), is characterized by sustained inflammation and failed inflammation resolution. Despite the great advances in pharmaceutical therapy, CVD remains the leading cause of death worldwide. A deeper understanding of the mechanisms that promote atherosclerotic lesion onset and progression may identify novel therapeutic targets for the prevention and treatment of the disease. The aim of the present Special Issue is to attract high-quality articles that focus on potential innovative therapeutic strategies for the immune, cellular, and molecular mechanisms of atherosclerosis. We welcome opinions, brief reports, communications, and research articles, as well as reviews.

Dr. Catherine Martel

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com